Human Amniotic-Derived Mesenchymal Stem Cells
Chronic Kidney Disease
Explore 30 assets in Chronic Kidney Disease →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04592640CT.gov Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Amniotic-Derived Mesenchymal Stem Cells (this asset) | The First Affiliated Hospital with Nanjing Medical University | Early P1 | C · 39 |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BBB |
| Semaglutide | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Watson Pharmaceuticals | P4 | BBB |
| Clopidogrel | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Aspirin | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Retatrutide | Eli Lilly and Company | P3 | BB |
| Simethicone | Alfredo Di Leo | P4 | BB |
| Cephalexin | Mayo Clinic | P4 | BB |
+42 more in the Chronic Kidney Disease cohort
Other indications for Human Amniotic-Derived Mesenchymal Stem Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Calciphylaxis | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Amniotic-Derived Mesenchymal Stem Cells in Chronic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-amniotic-derived-mesenchymal-stem-cells-chronic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →